Therefore, the primary aim of this study was to evaluate the diagnostic usefulness of serum RLN2 and YKL-40 as biomarkers in patients with colorectal cancer, compared to conventional ones (CEA and CA19-9), while the secondary aim was to explore their associations with tumor stage and therapy. This evidence concerns the gene CHI3L1 and colorectal cancer.